Zoetis Inc. (NYSE:ZTS) Shareholders Set to Receive $0.53 Quarterly Dividend

Zoetis Inc. (NYSE:ZTS) announced a quarterly dividend on Thursday, October 8th. Stockholders of record on Friday, October 30th will be given a dividend of $0.53 per share on Tuesday, December 1st. This represents a $2.12 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, October 30th.

Zoetis has raised its dividend payment by an average of 0.2%per year over the last three years and has raised its dividend annually for the last 14 consecutive years. Zoetis has a payout ratio of 31.0% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Zoetis to earn $6.33 per share next year, which means the company should continue to be able to cover its $2.12 annual dividend with an expected future payout ratio of 33.5%.

Zoetis Price Performance

ZTS opened at $73.08 on Friday. The company has a market capitalization of $30.20 billion, a P/E ratio of 12.04, a PEG ratio of 1.67 and a beta of 0.74. The company has a 50-day moving average of $73.97 and a 200-day moving average of $84.93. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. Zoetis has a 1-year low of $68.77 and a 1-year high of $148.30.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. The business had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company’s quarterly revenue was down .2% compared to the same quarter last year. During the same quarter last year, the company posted $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities analysts expect that Zoetis will post 6.2 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostics and other products for pets and livestock. Its portfolio is designed to help prevent and treat disease, improve animal health and support veterinary care.

The company serves the companion animal market with products for dogs, cats and other pets, including parasiticides, vaccines, dermatology treatments and pain-management therapies. Zoetis also provides animal health products for cattle, swine, poultry, fish and other livestock, along with diagnostic instruments, tests and services used by veterinarians and producers.

Zoetis was established as an independent public company in 2013 after being separated from Pfizer, which had operated the business as Pfizer Animal Health.